Respiratory diseases affect millions of people worldwide and are associated with considerable morbidity and mortality7,8

Aerosol therapy is the cornerstone of treatment for respiratory conditions, but challenges exist9-12

Difficulties with device use

Correct technique is required to administer medication via inhaler, which can be affected by age, manual dexterity, cognitive ability and coordination skills9,10

Patient distress during respiratory exacerbations

On presentation, children may be crying or in distress, which may negatively impact the dose delivered during inhaled therapy11,12

Support during escalation of care

Patients admitted to hospital during exacerbations may receive respiratory support (e.g., high-flow therapy [HF]) or ventilatory support (e.g., non-invasive ventilation [NIV], invasive mechanical ventilation [IMV])9,10 and require concomitant aerosol therapy


In asthma, Aerogen supports patient care in response to aerosolised medication2,3

In a study of self-ventilating (SV) children with a moderate-to-severe asthma exacerbation:

Significantly fewer bronchodilator treatments were required to achieve symptom control with Aerogen Ultra vs a jet nebuliser, irrespective of disease severity2

Median (IQR) number of treatments: 2.0 (1–3) vs 3.0 (2–5); P<0.001.

Defined as achieving a mild asthma score following an asthma exacerbation.


In COPD, Aerogen supports effective drug delivery3

In a study of patients with stable moderate-to-severe COPD receiving NIV:

~4x more medication was delivered to the lungs using Aerogen during NIV vs a jet nebuliser3

Mean (±SD) lung deposition: 12.05 ± 2.96% vs 3.14 ± 1.71%; P<0.001.

Aerogen helps to address some of the challenges of aerosol drug delivery in the treatment of respiratory disease:

Difficulties with inhaler use

Aerogen is quick and easy to set up1
No added flow required1

Patient distress during exacerbations

Aerogen is virtually silent,1,13 keeping a calm environment for your patients

Support during escalation of care

One system used throughout a patient’s respiratory journey (IMV, NIV, HF, SV),1 supporting continuity of care1

Aerogen Solo

Aerogen Solo can support aerosol drug delivery at every stage of a patient’s respiratory journey: during IMV, NIV, HF and SV.1

  • Quick and easy to set up1
  • Virtually silent1,13
  • Single patient use1
  • 28 days intermittent or 7 days continuous use1
  • No added flow1
  • Refill medication cup without opening the circuit1
  • 6 mL cup1
  • Can be placed at the wye or at the humidifier1

Aerogen Solo, virtually silent
Invasive mechanical ventilation enquiries


The Aerogen team and our representatives are available globally to answer your questions, provide an online demonstration and place orders

How can we help

COPD, chronic obstructive pulmonary disease; DALYs, disability-adjusted life years; HF, high-flow therapy; IMV, invasive mechanical ventilation; IQR, interquartile range; NIV, non-invasive ventilation; SD, standard deviation; SV, self-ventilating.

  1. 30-354 Rev U Aerogen Solo System Instruction Manual.
  2. Moody GB, Luckett PM, Shockley CM, et al. Respir Care 2020;65(10):1451-1463.
  3. Li J, Zhao M, Hadeer M, Luo J, Fink JB. Respiration. 2019;98(5):401-409.
  4. Galindo-Filho VC, Alcoforado L, Rattes C, et al. Respir Med. 2019;153:60-67.
  5. Avdeev SN, Nuralieva GS, Soe AK, et al. J Aerosol Med Pulm Drug Deliv. 2021;34(6):358-365.
  6. Beuvon C, Coudroy R, Bardin J, et al. Respir Care. 2021;respcare.09242.
  7. Global burden of diseases, injuries, and risk factors study, 2019. eClinicalMedicine. 2023:101920.
  8. Safiri S, Carson-Chahhoud K, Noori M, et al. BMJ. 2022;378:e069679.
  9. 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: Accessed: May 2023.
  10. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for prevention, diagnosis and management of COPD, 2023. Available at: Accessed: May 2023. 
  11. Ari A. Ann Transl Med. 2021;9(7):593.
  12. Corcoran TE. Ann Transl Med. 2021;9(7):595.
  13. Aerogen Data on File